会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • 4,5-disubstituted-2-aminopyrimidines
    • 4,5-二取代-2-氨基嘧啶
    • US06600037B1
    • 2003-07-29
    • US09692368
    • 2000-10-19
    • Jeremy Martin DavisDavid Festus Charles Moffat
    • Jeremy Martin DavisDavid Festus Charles Moffat
    • C07D23942
    • C07D239/42A61K31/505C07D231/12C07D233/56C07D249/08C07D401/12C07D403/12
    • Pyrimidines of formla (1) are described: wherein R1 is a —XR6 group; R2 and R3 which may be the same or different is each a hydrogen or halogen atom or a group selected from an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, —OH, —OR10 [where R10 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group] —SH, —NO2, —CN, —SR10, —COR10, S(O)R10, —SO2R8, —SO2N(R8)(R9), —CO2R8, —CON(R8)(R9), —CSN(R8)(R9), —NH2 or substituted amino group; R4 is a X1R11 group where X1 is a covalent bond or a —C(R12)(R13)— [where each of R12 and R13 is a hydrogen or halogen atom or a hydroxyl, alkyl or haloalkyl group] or —C(O)— group and R11 is an optionally substituted phenyl, thienyl, thiazolyl or indolyl group; R5 is a halogen atom or an alkynyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis.
    • 描述了formla(1)的嘧啶:其中R1是-XR6基团; R2和R3可以相同或不同,各自为氢或卤素原子或选自任选取代的脂族,脂环族,杂脂族,杂环脂族, OH,-OR 10 [其中R 10是任选取代的脂族,脂环族,杂脂族,杂脂族,芳族或杂芳族基团] -SH,-NO 2,-CN,-SR 10,-COR 10,S(O)R 10,-SO 2 R 8,-SO 2 N (R8)(R9),-CO2R8,-CON(R8)(R9),-CSN(R8)(R9),-NH2或取代氨基; R4是X1R11基团,其中X1是共价键或-C (R 12)(R 13) - [其中R 12和R 13各自为氢或卤素原子或羟基,烷基或卤代烷基]或-C(O) - 基,R 11为任选取代的苯基,噻吩基,噻唑基或吲哚基 基团; R5是卤素原子或炔基;以及它们的盐,溶剂合物,水合物和N-氧化物。化合物是选择性KDR激酶和/或FGFr激酶抑制剂,并且可用于植物 治疗与血管生成相关的疾病状态。
    • 9. 发明授权
    • Processes for preparing aminophenylsulfonylureas, and intermediates therefor
    • 制备氨基苯磺酰脲的方法及其中间体
    • US06500952B1
    • 2002-12-31
    • US09664201
    • 2000-09-18
    • Gerhard SchnabelJan VermehrenLothar Willms
    • Gerhard SchnabelJan VermehrenLothar Willms
    • C07D23942
    • C07D521/00A01N47/36H01R33/06Y02A40/143
    • The invention relates to the preparation of compounds (I) in which A=H or acyl and R1, R21, R3, R, n, X, Y and Z are as defined in claim 1 by halogenation and rearrangement of compounds (II) (optionally salt) to give compounds (III) a) ammonolysis of (III) to (IV), reduction of the nitro group and reaction with carbamate (salts) (VI) of the formula Ar—OCO—N(M)—Het, where Ar=phenyl, M=H or cation and Het=heterocycle from formula (I), to give compounds (I) (A=H), or b) ammonolysis of (III) to (IV), reaction with carbamate (salt) (VI) and reduction of resulting compounds (VII) at the NO2 group to give compounds (I) (A=H), or c) reaction of (III) with cyanates and amines (VIII) of the formula HNR3—Het and reduction of the resulting compound (VII) at the NO2 group to give compounds (I) (A=H) and optional acylation if A is to be other than H. Compounds of the formulae (I) (A=H), (III), (IV), (V), (VI) (M=cation) and (VII) are novel.
    • 本发明涉及化合物(Ⅰ)的制备,其中A = H或酰基,R 1,R 21,R 3,R 4,n,X,Y和Z如权利要求1中所定义,通过卤化和重排化合物 任选的盐),得到化合物(III)a)(III)至(IV)的氨解,硝基的还原和与式Ar-OCO-N(M)-Het的氨基甲酸酯(盐)(VI)的反应, 其中Ar =苯基,M = H或阳离子和Het =来自式(I)的杂环,得到(III)至(IV)化合物(I)(A = H),orb)氨解,与氨基甲酸酯 (VI)和还原所得化合物(VII)在NO 2基团上得到化合物(I)(A = H),orc)(III)与式HNR3-Het的氰酸酯和胺(VIII)的反应,还原 所得到的化合物(Ⅶ)在NO2基团上得到化合物(I)(A = H),任选的酰化如果A不为H.式(I)(A = H),(III) (IV),(V),(VI)(M =阳离子)和(VII)是新颖的。